Sign in
TerminatedPhase 3

Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy

Key facts

Who runs it
Amryt Pharma
Where
Belgium, France, Germany, and Italy12 sites in 4 countriesChoose a country to see its sites
Status
Terminated
Phase
Phase 3
People taking part
1 person enrolled
Started
23 May 2025
Ended
11 Feb 2026
Type of study
Interventional
Treatments tested
  • Metreleptin
Record updated
22 July 2026
Why it stopped
This clinical trial was closed early due to no longer being a requirement to the European Medicines Agency.

Who can take part

Age
Up to 5 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • Confirmed diagnosis of Generalised Lipodystrophy
  • Metreleptin treatment naive

Who cannot take part

  • Weight <9 kg at Screening (Visit 1)

This trial has no sites in United States.

It has sites in 4 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is an open-label, Phase 3b study to evaluate effectiveness, safety and pharmacokinetic parameters of metreleptin in patients under 6 years of age with generalised lipodystrophy and associated diabetes mellitus and/or hypertriglyceridaemia

The group in the trial

  • MetreleptinTreatment being tested

    Metreleptin \[Recombinant-methionyl human Leptin; rmetHuLeptin\] for daily injection is a sterile, white, solid lyophilised cake

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Open-label, Phase 3b Study to Evaluate Effectiveness, Safety and Pharmacokinetic Parameters of Metreleptin in Patients Under 6 Years of Age With Generalised Lipodystrophy and Associated Diabetes Mellitus and/or Hypertriglyceridaemia
Record updated
22 July 2026